Skip to main content
letter
. 2024 Feb 29;109(7):2309–2315. doi: 10.3324/haematol.2023.284271

Figure 1.

Figure 1.

Establishment of novel Down syndrome acute lymphoblastic leukemia models for preclinical testing. (A) Constitutive phosphorylation of Stat5 and Erk1/2 in KRASG12D and BCR-ABL-expressing murine cells (starved for 6 hours). (B) Growth of murine wild-type (WT)-KRASG12D, Tc1-KRASG12D and Ts1/Cdkn2a-KRASG12D cells with or without cytokines (Il-7, Scf and Flt3-L, 10 ng/mL) over 6 days. (C) Kaplan-Meier analysis comparing survival of primary (1R) and secondary (2R) sub-lethally irradiated recipient mice engrafted with 1-2x106 Tc1-KRASG12D (1R N=4, 2R N=6), WT-KRASG12D (1R N=5, 2R N=6) and Ts1Rhr/Cdkn2a-KRASG12D (1R N=5, 2R N=6) cell lines; **P<0.01. (D) Phenotype of the murine cell lines assessing surface expression of BP1 and CD24 (phenotype of the WT-BCR-ABL and Tc1-BCR-ABL cell lines are in the Online Supplementary Figure 1F), and representative flow plots showing phenotype of mCherry-positive cell lines in primary and secondary recipients. w/: with; w/o: without. Cyt: cytokine.